Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) has listed a series of significant accomplishments in its pursuit of developing transformative medicines to treat rare diseases, marking 2023 as a groundbreaking year for the biopharmaceutical company.
In a statement, CEO Philip Young highlighted the company's major achievements, stating: "2023 was a remarkable year that witnessed the company make important advancements in clinical development of our proprietary pharmaceutical products and the acquisition and commercial launch of Altemia, our novel medical formulation for Sickle Cell Disease."
In April 2023, the company acquired Altemia, a novel medical formulation designed specifically for the treatment of Sickle Cell Disease, marking a significant step in addressing this rare condition. The company appointed Baxter Phillips III as the COO of Lobe and president of Altemia, strengthening its leadership team. Lobe also signed an exclusive collaboration with Pentec Health for the launch and distribution of Altemia.
Altemia recorded a revenue of C$1.1 million, indicating a positive reception and early success in the market. Lobe Sciences completed the first Phase 1 study evaluating the pharmacokinetics (PK) and safety of L-130, a proprietary pharmaceutical product. The study demonstrated the 12-month shelf stability of L-130, highlighting its potential as a preferred drug candidate.
"With the completion of the first-in-man clinical work on L-130 we have demonstrated that we have a very valuable pharmaceutical product with a more predictable PK stability profile that we believe the preferred drug candidate for any company pursuing the development of serotonin targeted therapeutics, including psychedelic uses and non-psychedelic dosing as we are pursuing,” Young continued.
Looking ahead to 2024, Young anticipates a promising year, particularly with the positive reception of Altemia, and plans to build on the momentum gained in 2023.
The company said it will be meeting with prospective investors and corporate partners during the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco from January 8 to 11 and interested parties can contact ir@lobesciences.com to schedule a meeting.
Lobe Sciences is a biopharmaceutical company focused on developing transformative medicines to treat rare diseases. The company, through collaborations with industry-leading partners, is additionally engaged in drug research and development using non-hallucinatory doses of stabilized psilocin-based compounds to address unmet medical needs in orphan neurological therapeutic applications.